Chimiothérapie systémique des cancers biliaires avancés

Translated title of the contribution: Systemic chemotherapy for advanced biliary cancers

David Malka, Valérie Boige, Michel Ducreux

Research output: Contribution to journalShort surveypeer-review


Gemcitabine-cisplatin combination (GEMCIS regimen) is the first standard for first-line palliative chemotherapy in patients with advanced biliary tract cancer and correct performance status. Despite the absence of randomized controlled trials comparing GEMCIS and gemcitabine-oxaliplatin (GEMOX) regimens, the latter represents an interesting option. No data allow currently to define a standard for second-line and further therapies. Future therapeutic advances will likely come from the combination of targeted agents with chemotherapy, with selection of patients on tumor oncogenic alterations of interest.

Translated title of the contributionSystemic chemotherapy for advanced biliary cancers
Original languageFrench
Pages (from-to)283-288
Number of pages6
Issue number3
StatePublished - May 2011
Externally publishedYes


  • Biliary tract cancer
  • Chemotherapy
  • Targeted therapy


Dive into the research topics of 'Systemic chemotherapy for advanced biliary cancers'. Together they form a unique fingerprint.

Cite this